Renal cell carcinoma is one of the most common urinary system tumors in adults, it is usually asymptomatic in its early stage and the patients are often diagnosed late. MicroRNA has a higher diagnostic accuracy than traditional markers and may become a new type of early diagnostic biomarker for kidney cancer. Three computational methods and several bioinformatic methods including PPI network, overall survival analysis and enrichment analysis were used to identify the significant differentially expressed miRNAs. Thirteen miRNAs that were significantly differentially expressed in RCC patients were identified, 10 of them have been proved to be associated with kidney cancer in other studies, miR-576, miR-616 and miR-133a-2 are three newly discovered biomarkers of RCC in this study. We found that the target genes of miR-576 (CUL3 and RAC1) are involved in the regulation of multiple cancer-related biological pathways, and the target gene of miR-616 (ASB13 and FBXW2) has been reported to be associated with the development of other cancers. Our findings may have guiding significance for the early diagnosis of renal cell carcinoma.

中文翻译：

---

肾癌早期诊断生物标志物的计算鉴定和分析。

肾细胞癌是成人最常见的泌尿系统肿瘤之一，通常在其早期是无症状的，并且患者通常被诊断为晚期。MicroRNA具有比传统标记更高的诊断准确性，并且可能成为肾癌的一种新型早期诊断生物标记。三种计算方法和几种生物信息学方法（包括PPI网络，总体存活率分析和富集分析）用于鉴定显着差异表达的miRNA。在其他研究中，鉴定出13种在RCC患者中表达差异显着的miRNA，其中10种已被证明与肾癌相关，miR-576，miR-616和miR-133a-2是在RCC中新发现的三种生物标志物。这项研究。我们发现miR-576的靶基因（CUL3和RAC1）参与了多种与癌症相关的生物途径的调控，并且据报道miR-616的靶基因（ASB13和FBXW2）与发育有关其他癌症。我们的发现对于肾细胞癌的早期诊断可能具有指导意义。